Focus on HIV Care

Back to articles

Newly Approved HIV Drugs Reduce Pill Burden


Two new medications—a protease inhibitor and a nucleoside reverse transcriptase inhibitor (NRTI)—feature once-daily dosing, an important element in maintaining adherence to complicated antiretroviral regimens. Atazanavir (Reyataz—Bristol-Myers Squibb), dosed once daily with food, will be used in combination with other antiretroviral agents for treatment of patients with HIV-1 infection. Emtricitabine (Emtriva—Gilead) is a once-daily, one-capsule NRTI approved for treatment of HIV-1 infection in adults in combination with other antiretroviral medications.


Reyataz Web site.

FDA talk paper on Reyataz.

Emtriva Web site.

Raffi F et al. Phase III results for Emtriva. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 14, 2003.